Lupin shares gains 10 percent after getting EIR from USFDA for Goa plant


Published On: Tuesday, December 14, 2021 | By:

Lupin shares gains 10 percent  after getting EIR from USFDA for Goa plant

Shares of Lupin surged 10 per cent to Rs 972.50 on the BSE in Tuesday’s intra-day trade, after the drug-maker announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), the Mumbai-headquartered company said in a regulatory exchange filing."We are very happy to have received the EIR from US FDA with Voluntary Action Indicated classification for our Goa plant. This is a significant milestone as we build back our reputation of being best-in-class in Quality and Compliance. We are committed to manufacture and supply products of the highest quality from all our manufacturing sites." said Vinita Gupta, CEO, Lupin.

Commenting on the development, Nilesh Gupta, managing director, Lupin said: “This is a very positive development and we are delighted with the news of the change in classification of our Goa site. The Goa site has a very important place in the US market with the number of affordable, quality medicines we supply, and we now look forward to new products flowing out of the site again.”

We are on Telegram!

Telegram Logo

JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.

Click Here!

Follow Us On: